Clinical Activity and Tolerability of Enzalutamide ( MDV3100) in Patients With Metastatic, Castration- Resistant Prostate Cancer Who Progress After Docetaxel and Abiraterone Treatment

S. Badrising; V. van der Noort; I.M. van Oort; H.P. van den Berg; M. Los; P. Hamberg; J.L. Coenen; A.J.M. van den Eertwegh; I.J. de Jong; E.D. Kerver; H. van Tinteren; A.M. Bergman

doi:https://doi.org/10.1002/cncr.28518

Clinical Activity and Tolerability of Enzalutamide ( MDV3100) in Patients With Metastatic, Castration- Resistant Prostate Cancer Who Progress After Docetaxel and Abiraterone Treatment

S. Badrising, V. van der Noort, I.M. van Oort, H.P. van den Berg, M. Los, P. Hamberg, J.L. Coenen, A.J.M. van den Eertwegh, I.J. de Jong, E.D. Kerver, H. van Tinteren, A.M. Bergman

Medical oncology (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

127 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	968-975
Journal	Cancer
Volume	120
Issue number	7
DOIs	https://doi.org/10.1002/cncr.28518
Publication status	Published - 2014

Access to Document

https://doi.org/10.1002/cncr.28518

Cite this

Badrising, S., van der Noort, V., van Oort, I. M., van den Berg, H. P., Los, M., Hamberg, P., Coenen, J. L., van den Eertwegh, A. J. M., de Jong, I. J., Kerver, E. D., van Tinteren, H., & Bergman, A. M. (2014). Clinical Activity and Tolerability of Enzalutamide ( MDV3100) in Patients With Metastatic, Castration- Resistant Prostate Cancer Who Progress After Docetaxel and Abiraterone Treatment. Cancer, 120(7), 968-975. https://doi.org/10.1002/cncr.28518

@article{4c1660c2a4604d1b8310420abdb27ed6,

title = "Clinical Activity and Tolerability of Enzalutamide ( MDV3100) in Patients With Metastatic, Castration- Resistant Prostate Cancer Who Progress After Docetaxel and Abiraterone Treatment",

author = "S. Badrising and {van der Noort}, V. and {van Oort}, I.M. and {van den Berg}, H.P. and M. Los and P. Hamberg and J.L. Coenen and {van den Eertwegh}, A.J.M. and {de Jong}, I.J. and E.D. Kerver and {van Tinteren}, H. and A.M. Bergman",

year = "2014",

doi = "https://doi.org/10.1002/cncr.28518",

language = "Undefined/Unknown",

volume = "120",

pages = "968--975",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "7",

}

Badrising, S, van der Noort, V, van Oort, IM, van den Berg, HP, Los, M, Hamberg, P, Coenen, JL, van den Eertwegh, AJM, de Jong, IJ, Kerver, ED, van Tinteren, H & Bergman, AM 2014, 'Clinical Activity and Tolerability of Enzalutamide ( MDV3100) in Patients With Metastatic, Castration- Resistant Prostate Cancer Who Progress After Docetaxel and Abiraterone Treatment', Cancer, vol. 120, no. 7, pp. 968-975. https://doi.org/10.1002/cncr.28518

Clinical Activity and Tolerability of Enzalutamide ( MDV3100) in Patients With Metastatic, Castration- Resistant Prostate Cancer Who Progress After Docetaxel and Abiraterone Treatment. / Badrising, S.; van der Noort, V.; van Oort, I.M. et al.
In: Cancer, Vol. 120, No. 7, 2014, p. 968-975.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Clinical Activity and Tolerability of Enzalutamide ( MDV3100) in Patients With Metastatic, Castration- Resistant Prostate Cancer Who Progress After Docetaxel and Abiraterone Treatment

AU - Badrising, S.

AU - van der Noort, V.

AU - van Oort, I.M.

AU - van den Berg, H.P.

AU - Los, M.

AU - Hamberg, P.

AU - Coenen, J.L.

AU - van den Eertwegh, A.J.M.

AU - de Jong, I.J.

AU - Kerver, E.D.

AU - van Tinteren, H.

AU - Bergman, A.M.

PY - 2014

Y1 - 2014

U2 - https://doi.org/10.1002/cncr.28518

DO - https://doi.org/10.1002/cncr.28518

M3 - Article

C2 - 24382803

SN - 0008-543X

VL - 120

SP - 968

EP - 975

JO - Cancer

JF - Cancer

IS - 7

ER -